Nnexxahealth
The Inaugural Issue
Counting on Europe
Bayer built the cell and gene therapy toolbox. Now Europe has to decide whether to pay for it.
Issue 01 · Autumn 2026
The Inaugural Issue
From the future of cell and gene therapy and Europe’s race to build biotech champions, to the life sciences cluster taking shape in Barcelona, nexxahealth’s first issue explores what comes next for European health and life sciences. We look at the latest medicines and technologies approved in Europe, investment and competitiveness, medicine shortages, prevention and the future of healthcare, alongside voices from patients, policymakers, scientists and industry leaders shaping what happens next.
In this issue
The full table of contents
Every piece in Issue 01, with its section and its page number, exactly as it runs in the magazine.